Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Double Blind, Multicentre, Placebo Controlled Phase III Study of the Safety and Tolerability Following Administration of Live Attenuated JE Vaccine (ChimeriVax™-JE)

NCT00314132 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00314132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00314132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Double Blind, Multicentre, Placebo Controlled Phase III Study of the Safety and Tolerability Following Administration of Live Attenuated JE Vaccine (ChimeriVax™-JE)
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2005
Completion date
November 30, 2006
Enrollment
2,004 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

encephalitis, japanese encephalitis